Common Stock, $0.0001 par value per share
- Symbol
- GOSS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
Gossamer Bio, Inc.
GOSSNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On September 25, 2026, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1), and the minimum bid price matter is now closed.…
Company context
Gossamer Bio is a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.
Current securities
Registered securities in this filing
GOSSAMER BIO, INC. · 8-K · Filed 2026-09-28
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On September 25, 2026, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1), and the minimum bid price matter is now closed. The letter was pursuant to a previous letter received on April 8, 2026 from the Listing Qualifications Department of Nasdaq, indicating, as previously reported, that the Company was not then in compliance with the minimum bid price requirement because its common stock had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days. As previously disclosed, on September 10, 2026, the Company effected a 1-for-80 reverse stock split of its common stock, and the Company’s common stock began trading on a split-adjusted basis on the Nasdaq Global Select Market on September 11, 2026.